← Leaderboards
Timothy Cloughesy
University Of California Los Angeles
$3,024,113
Attributed
$4,639,916
Total exposure
50
Grants
34
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $623K · FY2005–25$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$4,639,916 · 50
By mechanism
R01$2,423,705 · 1
M01$952,690 · 41
U01$719,668 · 1
P50$368,742 · 1
P41$175,111 · 6
Top collaborators
- Benjamin M. Ellingson4 shared
- David A. Nathanson4 shared
Most similar at University Of California Los Angeles
Same institution · by research overlap
- Erina Vlashi$2,767,478
Others in their field
Top investigators on “Research Personnel”
- David Heimbrook · Leidos Biomedical Research, Inc.$701,463,488
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Leonard Freedman · Leidos Biomedical Research, Inc.$557,978,666
- Tracy L Nolen · Research Triangle Institute$474,487,152
- David R. Weir · University Of Michigan At Ann Arbor$364,053,504
- Judith S. Currier · University Of California Los Angeles$284,675,012
Research focus
Research PersonnelInstitutionFundingResourcesGrantUnited States National Institutes Of HealthComputer Retrieval Of Information On Scientific Projects DatabaseSourceClinical ResearchRecurrenceTumorGlioblastomaGliomaResponseSafetyDrug KineticsMalignant GliomaEpidermal Growth Factor ReceptorOperative Surgical ProceduresDiagnosisClinical TrialsHuman SubjectMaximum Tolerated DoseMagnetic Resonance Imaging
Grant awards (70)
Role of decorin and diffusion MRI in anti-VEGF efficacy for recurrent glioblastoma$607,842
R01 · FY2025 · CA
Role of decorin and diffusion MRI in anti-VEGF efficacy for recurrent glioblastoma$587,142
R01 · FY2024 · CA
Role of decorin and diffusion MRI in anti-VEGF efficacy for recurrent glioblastoma$605,684
R01 · FY2023 · CA
Role of decorin and diffusion MRI in anti-VEGF efficacy for recurrent glioblastoma$623,037
R01 · FY2022 · CA
Career Enhancement Program$72,083
P50 · FY2021 · CA · contact PI
Career Enhancement Program$73,659
P50 · FY2020 · CA · contact PI
Career Enhancement Program$72,083
P50 · FY2019 · CA · contact PI
Career Enhancement Program$77,537
P50 · FY2018 · CA · contact PI
Career Enhancement Program$73,380
P50 · FY2017 · CA · contact PI
UCLA IRB # 06-04-016 "PHASE II TRIAL OF BEVACIZUMAB IN COMBINATION WITH TEMOZ$141,075
M01 · FY2010 · RR · contact PI
UCLA IRB # 06-04-104 "A PHASE I/II, DUAL-CENTER, OPEN-LABEL TRIAL OF THE SAFE$27,029
M01 · FY2010 · RR · contact PI
UCLA IRB 08-09-042: PHASE I TRIAL OF AFLIBERCEPT (VEGF TRAP) WITH RADIATION THE$9,888
M01 · FY2010 · RR · contact PI
PHASE I/II STUDY OF OSI-774 (ERLOTINIB) AND CCI-779 (TEMSIROLIMUS) IN PATIENT$659
M01 · FY2010 · RR · contact PI
UCLA IRB # 06-04-016 "PHASE II TRIAL OF BEVACIZUMAB IN COMBINATION WITH TEMOZ$170,248
M01 · FY2009 · RR · contact PI
PHASE I/II STUDY OF OSI-774 (ERLOTINIB) AND CCI-779 (TEMSIROLIMUS) IN PATIENT$35,342
M01 · FY2009 · RR · contact PI
UCLA IRB (PENDING) "A PHASE I/II STUDIES OF BAY 43-9006 (SORAFENIB) IN COMBIN$23,705
M01 · FY2009 · RR · contact PI
UCLA IRB # 06-04-104 "A PHASE I/II, DUAL-CENTER, OPEN-LABEL TRIAL OF THE SAFE$15,947
M01 · FY2009 · RR · contact PI
UCLA IRB #05-12-061 "A PHASE I STUDY OF VORINOSTAT (SUBEROYLANILIDE HYDROXAMI$2,155
M01 · FY2009 · RR · contact PI
PHASE II SINGLE ARM TRIAL OF VEGF TRAP IN PATIENTS WITH RECURRENT TEMOZOLOMIDE-$1,724
M01 · FY2009 · RR · contact PI
Consortium Therapeutic Studies of Primary Central Nervous System Malignancies$146,647
U01 · FY2008 · CA · contact PI
UCLA IRB # 06-04-016 "PHASE II TRIAL OF BEVACIZUMAB IN COMBINATION WITH TEMOZ$101,598
M01 · FY2008 · RR · contact PI
"A PHASE I/II STUDIES OF BAY 43-9006 (SORAFENIB) IN COMBIN$12,477
M01 · FY2008 · RR · contact PI
PHASE I/II STUDY OF OSI-774 (ERLOTINIB) AND CCI-779 (TEMSIROLIMUS) IN PATIENT$12,120
M01 · FY2008 · RR · contact PI
RECURRENT TEMOZOLOMIDE-RESISTANT MALIGNANT GLIOMAS$3,564
M01 · FY2008 · RR · contact PI
CONSORTIUM THERAPEUTIC STUDIES OF PRIMARY CENTRAL NERVI*$2,576
P41 · FY2008 · RR · contact PI
CLINICAL TRIAL: A PHASE II TRIAL OF POLY-ICLC IN PATIENTS WITH RECURRENT ANAPLAS$1,783
M01 · FY2008 · RR · contact PI
A BIOMARKER AND PHASE II STUDY OF GW 572016 IN RECURRENT MALIGNANT GLIOMA (NA$1,426
M01 · FY2008 · RR · contact PI
Consortium Therapeutic Studies of Primary Central Nervous System Malignancies$145,196
U01 · FY2007 · CA · contact PI
PHASE II TRIAL OF EMD 121974 FOR RECURRENT GLIOBLASTOMA: A CLINICAL TRIAL WIT$66,284
M01 · FY2007 · RR · contact PI
CONSORTIUM THERAPEUTIC STUDIES OF PRIMARY CENTRAL NERVI*$20,076
P41 · FY2007 · RR · contact PI
UCLA IRB #05-12-061 "A PHASE I STUDY OF VORINOSTAT (SUBEROYLANILIDE HYDROXAMI$12,021
M01 · FY2007 · RR · contact PI
UCLA IRB # 06-04-016 "PHASE II TRIAL OF BEVACIZUMAB IN COMBINATION WITH TEMOZ$11,677
M01 · FY2007 · RR · contact PI
A PHASE II TRIAL OF POLY-ICLC IN PATIENTS WITH RECURRENT ANAPLASTIC GLIOMA N$6,182
M01 · FY2007 · RR · contact PI
UCLA IRB (PENDING) "A PHASE I/II STUDIES OF BAY 43-9006 (SORAFENIB) IN COMBIN$5,495
M01 · FY2007 · RR · contact PI
A BIOMARKER AND PHASE II STUDY OF GW 572016 IN RECURRENT MALIGNANT GLIOMA (NA$3,091
M01 · FY2007 · RR · contact PI
PHASE I/II STUDY OF OSI-774 (ERLOTINIB) AND CCI-779 (TEMSIROLIMUS) IN PATIENT$1,718
M01 · FY2007 · RR · contact PI
Consortium Therapeutic Studies of Primary Central Nervi*$145,177
U01 · FY2006 · CA · contact PI
A PHASE II TRIAL OF POLY-ICLC IN PATIENTS WITH RECURRENT ANAPLASTIC GLIOMA N$86,483
M01 · FY2006 · RR · contact PI
PHASE II TRIAL OF EMD 121974 FOR RECURRENT GLIOBLASTOMA: A CLINICAL TRIAL WIT$14,414
M01 · FY2006 · RR · contact PI
A MODIFIED PHASE I/II TRIAL OF RAPAMYCIN IN PATIENTS WITH MALIGNANT GLIOMAS$8,008
M01 · FY2006 · RR · contact PI
A PHASE II TRIAL OF STI-571 ( NSC 716051) IN PATIENTS WITH RECURRENT MENINGIO$6,006
M01 · FY2006 · RR · contact PI
CONSORTIUM THERAPEUTIC STUDIES OF PRIMARY CENTRAL NERVI*$5,078
P41 · FY2006 · RR · contact PI
ZD1839 FOR TREATMENT OF RECURRENT OR PROGRESSIVE MALIGNANT ASTROCYTOMA OR GLI$801
M01 · FY2006 · RR · contact PI
A PHASE I/II TRIAL OF OSI-774 IN PATIENTS WITH RECURRENT MALIGNANT GLIOMAS AN$400
M01 · FY2006 · RR · contact PI
A MULTICENTER, OPEN-LABEL, RANDOMIZED, UNCONTROLLED, PHASE IIA TRIAL IN SUBJE$400
M01 · FY2006 · RR · contact PI
Consortium Therapeutic Studies of Primary Central Nervi*$143,873
U01 · FY2005 · CA
A PHASE II TRIAL OF POLY-ICLC IN PATIENTS WITH RECURRENT ANAPLASTIC GLIOMA N$92,974
M01 · FY2005 · RR
A MODIFIED PHASE I/II TRIAL OF RAPAMYCIN IN PATIENTS WITH MALIGNANT GLIOMAS$10,106
M01 · FY2005 · RR
CONSORTIUM THERAPEUTIC STUDIES OF PRIMARY CENTRAL NERVI*$9,831
P41 · FY2005 · RR
A PHASE II TRIAL OF STI-571 ( NSC 716051) IN PATIENTS WITH RECURRENT MENINGIO$4,909
M01 · FY2005 · RR
A PHASE I/II TRIAL OF OSI-774 IN PATIENTS WITH RECURRENT MALIGNANT GLIOMAS AN$4,331
M01 · FY2005 · RR
PHASE I/II OF R115777 IN PATIENTS WITH RECURRENT MALIGNANT GLIOMAS$3,753
M01 · FY2005 · RR
ZD1839 FOR TREATMENT OF RECURRENT OR PROGRESSIVE MALIGNANT ASTROCYTOMA OR GLI$3,753
M01 · FY2005 · RR
PHASE II TRIAL OF POLY-ICLC FOR GLIOBLASTOMA [NABTC 01-05]$3,465
M01 · FY2005 · RR
PHASE I-II TRIAL OF STI-571 (NSC 716051) IN PATIENTS WITH RECURRENT MALIGNANT$2,021
M01 · FY2005 · RR
Consortium Therapeutic Studies of CNS Malignancies$138,775
U01 · FY2004 · CA
QUANTIFIED GENE EXPRESSION IMPROVES PROGNOSIS$27,525
P41 · FY2004 · RR
Phase I/II Trial of OSI-774 in Patients with Recurrent$19,646
M01 · FY2004 · RR
Modified Phase I/II Trial of Rapamycin in Patients wit$8,459
M01 · FY2004 · RR
Phase I/II Trial of CCI-779 in Patients with Malignant Gliomas (NABTC 01-01)$6,821
M01 · FY2004 · RR
Phase I/II of R115777 for Recurrent Malignant Gliomas$6,276
M01 · FY2004 · RR
ZD1839 for Treatment of Recurrent or Progressive Malignant Astrocytoma or Gli...$2,183
M01 · FY2004 · RR
Phase II Evaluation of Fenretinide (NSC 374551) as a S$273
M01 · FY2004 · RR
GENE EXPRESSION PROGNOSIS &TRTMT RESPONSE STRATIFICATION IN PATS W/ GLIOMA$0
P41 · FY2002 · RR
GENE EXPRESSION PROGNOSIS &TRTMT RESPONSE STRATIFICATION IN PATS W/ GLIOMA$48,533
P41 · FY2001 · RR
PHASE 2 TRIAL OF THYMIDINE/CARBOPLATIN THERAPY OF GLIOMA$0
M01 · FY2001 · RR
GENE EXPRESSION PROGNOSIS &TRTMT RESPONSE STRATIFICATION IN PATS W/ GLIOMA$0
P41 · FY2001 · RR
GENE EXPRESSION PROGNOSIS &TRTMT RESPONSE STRATIFICATION IN PATS W/ GLIOMA$0
P41 · FY2001 · RR
PHASE I/II TRIAL OF IRONSTECAN IN PATIENTS WITH GLIOMA$0
M01 · FY2001 · RR
GENE EXPRESSION PROGNOSIS &TRTMT RESPONSE STRATIFICATION IN PATS W/ GLIOMA$61,492
P41 · FY2000 · RR